Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.

Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L.

J Med Chem. 2009 Nov 12;52(21):6716-23. doi: 10.1021/jm901016k. Erratum in: J Med Chem. 2009 Dec 24;52(24):8058.

2.

Small-Molecule Inhibitors of Vaccinia-H1-Related Phosphatase VHR.

Tautz L, Mustelin T, Wu S, Vossius S, Rahmouni S, Vasile S, Sergienko E, Stonich D, Yuan H, Su Y, Dahl R, Mostofi Y, Chung TDY.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2009 Oct 31 [updated 2010 Oct 4].

3.

Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.

Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, Tautz L, Boniver J, Mustelin T, Rahmouni S.

BMC Cancer. 2008 May 27;8:147. doi: 10.1186/1471-2407-8-147.

4.

Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening.

Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ.

ChemMedChem. 2008 Jun;3(6):877-80. doi: 10.1002/cmdc.200700348. No abstract available.

PMID:
18236492
5.

Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.

Pavic K, Rios P, Dzeyk K, Koehler C, Lemke EA, Köhn M.

ACS Chem Biol. 2014 Jul 18;9(7):1451-9. doi: 10.1021/cb500240n. Epub 2014 May 9.

PMID:
24798147
6.

Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects.

Shi Z, Tabassum S, Jiang W, Zhang J, Mathur S, Wu J, Shi Y.

Chembiochem. 2007 Nov 23;8(17):2092-9.

PMID:
17933004
7.

Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

Zhou H, Aguilar A, Chen J, Bai L, Liu L, Meagher JL, Yang CY, McEachern D, Cong X, Stuckey JA, Wang S.

J Med Chem. 2012 Jul 12;55(13):6149-61. doi: 10.1021/jm300608w. Epub 2012 Jul 2.

8.

Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity.

Havrylyuk D, Zimenkovsky B, Vasylenko O, Gzella A, Lesyk R.

J Med Chem. 2012 Oct 25;55(20):8630-41. doi: 10.1021/jm300789g. Epub 2012 Oct 9.

PMID:
22992049
9.

Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.

El-Dakdouki MH, Adamski N, Foster L, Hacker MP, Erhardt PW.

J Med Chem. 2011 Dec 8;54(23):8224-7. doi: 10.1021/jm200984x. Epub 2011 Nov 4.

PMID:
22011244
10.

Specificity profiling of dual specificity phosphatase vaccinia VH1-related (VHR) reveals two distinct substrate binding modes.

Luechapanichkul R, Chen X, Taha HA, Vyas S, Guan X, Freitas MA, Hadad CM, Pei D.

J Biol Chem. 2013 Mar 1;288(9):6498-510. doi: 10.1074/jbc.M112.449611. Epub 2013 Jan 15.

11.

Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.

Bindi S, Fancelli D, Alli C, Berta D, Bertrand JA, Cameron AD, Cappella P, Carpinelli P, Cervi G, Croci V, D'Anello M, Forte B, Giorgini ML, Marsiglio A, Moll J, Pesenti E, Pittalà V, Pulici M, Riccardi-Sirtori F, Roletto F, Soncini C, Storici P, Varasi M, Volpi D, Zugnoni P, Vianello P.

Bioorg Med Chem. 2010 Oct 1;18(19):7113-20. doi: 10.1016/j.bmc.2010.07.048. Epub 2010 Jul 25.

PMID:
20817473
12.

Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.

Prime ME, Courtney SM, Brookfield FA, Marston RW, Walker V, Warne J, Boyd AE, Kairies NA, von der Saal W, Limberg A, Georges G, Engh RA, Goller B, Rueger P, Rueth M.

J Med Chem. 2011 Jan 13;54(1):312-9. doi: 10.1021/jm101346r. Epub 2010 Dec 3.

PMID:
21128645
13.

Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.

Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang S.

J Med Chem. 2001 Dec 6;44(25):4313-24.

PMID:
11728179
14.

Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.

Teng M, Zhu J, Johnson MD, Chen P, Kornmann J, Chen E, Blasina A, Register J, Anderes K, Rogers C, Deng Y, Ninkovic S, Grant S, Hu Q, Lundgren K, Peng Z, Kania RS.

J Med Chem. 2007 Nov 1;50(22):5253-6. Epub 2007 Sep 21.

PMID:
17887663
15.

Screening multicomponent reactions for X-linked inhibitor of apoptosis-baculoviral inhibitor of apoptosis protein repeats domain binder.

Monfardini I, Huang JW, Beck B, Cellitti JF, Pellecchia M, Dömling A.

J Med Chem. 2011 Feb 10;54(3):890-900. Epub 2011 Jan 11.

PMID:
21241056
16.

Total syntheses of cytotoxic, naturally occurring kalasinamide, geovanine, and marcanine A.

Lang S, Groth U.

Angew Chem Int Ed Engl. 2009;48(5):911-3. doi: 10.1002/anie.200804388. No abstract available.

PMID:
19115341
17.

Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents.

Zhu SL, Wu Y, Liu CJ, Wei CY, Tao JC, Liu HM.

Eur J Med Chem. 2013 Jul;65:70-82. doi: 10.1016/j.ejmech.2013.04.044. Epub 2013 May 2.

PMID:
23693151
18.

Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.

Prinz H, Schmidt P, Böhm KJ, Baasner S, Müller K, Gerlach M, Günther EG, Unger E.

Bioorg Med Chem. 2011 Jul 15;19(14):4183-91. doi: 10.1016/j.bmc.2011.06.010. Epub 2011 Jun 12.

PMID:
21705223
19.

Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives.

Zheng LW, Zhu J, Zhao BX, Huang YH, Ding J, Miao JY.

Eur J Med Chem. 2010 Dec;45(12):5792-9. doi: 10.1016/j.ejmech.2010.09.041. Epub 2010 Oct 1.

PMID:
20947221
20.

Antiproliferative Activity of Amathaspiramide Alkaloids and Analogs.

Shimokawa J, Chiyoda K, Umihara H, Fukuyama T.

Chem Pharm Bull (Tokyo). 2016 Aug 1;64(8):1239-41. doi: 10.1248/cpb.c16-00256. Epub 2016 May 10.

Supplemental Content

Support Center